TICKERNOMICS Sign up
Last Update: 2024-03-28 02:10:20
Organon & Co. ( OGN ) https://www.organon.com
18.12USD
Sector:
Healthcare
Industry:
Drug Manufacturers-General
Country:
United States
1y
3y
5y
10y
Historical Returns*:
SPY
31.15%
-13.49%
OGN
SPY
32.74%
OGN
0.00%
SPY
92.93%
OGN
0.00%
SPY
224.41%
OGN
0.00%
*Assumes dividends reinvested
Market Stats:
Market Capitalization($MM)
Enterprise Value($MM)
Daily Volume(MM)
4555.26
12622.26
1.79
Valuation Metrics:
Price/Earnings Ratio
Price/Sales Ratio
Price/Book Value
FCF Yield(%)
Dividend Yield(%)
EV/EBITDA
7.79
0.74
-65.08
9.62
6.29
10.25
Profitability Stats:
Operating Margin %(ttm)
Gross Profit %(ttm)
EBITDA Margin %(ttm)
0.02
59.71
19.92
Shareholder Value Creation:
Cost of Capital %(est)
ROIC %(ttm)
ROCE %(ttm)
Beta
4.27
0.68
0.01
0.00
Other Earnings and Cash Flow Stats:
Organon & Co. ( OGN ) Net Income TTM ($MM) is 570.00
Organon & Co. ( OGN ) Operating Income TTM ($MM) is 916.23
Organon & Co. ( OGN ) Owners' Earnings Annual ($MM) is 0.00
Organon & Co. ( OGN ) Current Price to Owners' Earnings ratio is 0.00
Organon & Co. ( OGN ) EBITDA TTM ($MM) is 1315.00
Organon & Co. ( OGN ) EBITDA Margin is 19.92%
Capital Allocation:
Organon & Co. ( OGN ) has paid 1.12 dividends per share and bought back -0.45699999999999 million shares in the past 12 months
Organon & Co. ( OGN ) has reduced its debt by 161.0 million USD in the last 12 months
Capital Structure:
Organon & Co. ( OGN ) Interest-bearing Debt ($MM) as of last quarter is 8760
Organon & Co. ( OGN ) Annual Working Capital Investments ($MM) are -113
Organon & Co. ( OGN ) Book Value ($MM) as of last quarter is -70
Organon & Co. ( OGN ) Debt/Capital as of last quarter is -12515%
Other Balance Sheet Stats:
Organon & Co. ( OGN ) has 693 million in cash on hand as of last quarter
Organon & Co. ( OGN ) has 2918 million of liabilities due within 12 months, and long term debt 8760 as of last quarter
Organon & Co. ( OGN ) has 255 common shares outstanding as of last quarter
Organon & Co. ( OGN ) has 0 million USD of preferred stock value
Academic Scores:
Organon & Co. ( OGN ) Altman Z-Score is 1.04 as of last quarter
Organon & Co. ( OGN ) Piotroski Score is 5.00 as of last quarter
Corporate Governance:
Organon & Co. ( OGN ) largest shareholder is Dimensional Fund Advisors, Inc. owning 2033744 shares at 36.85 ($MM) value
Kirke Weaver(an insider) Bought 2720 shares of Organon & Co. ( OGN ) for the amount of $49939.20 on 2024-02-22
0.10% of Organon & Co. ( OGN ) is held by insiders, and 79.77% is held by institutions
Organon & Co. ( OGN ) went public on 2021-06-02
Other Organon & Co. ( OGN ) financial metrics:
FCF:570.00
Unlevered Free Cash Flow:1097.00
EPS:0.91
Operating Margin:0.02
Gross Profit Margin:59.71
Div. Payout Ratio%:48.94
Div. Growth YoY%:-20.00
Equity Return%:-331.43
Beta:0.00
Buffet's Owners Earnings:0.00
Price to Owner's Earnings:0.00
About Organon & Co. ( OGN ) :
Organon & Co. develops and delivers health solutions through a portfolio of preion therapies and medical devices within women's health in the United States and internationally. Its women's health portfolio comprises contraception and fertility brands, such as Nexplanon/Implanon, a long-acting reversible contraceptive; Nuvaring, a monthly vaginal contraceptive ring; Cerazette, a daily pill used to prevent pregnancy; Marvelon, progestin and estrogen used as daily pills to prevent pregnancy; Follistim AQ, used to promote the development of multiple ovarian follicles in assisted reproduction technology procedures; Elonva, an ovarian follicle stimulant; Ganirelix Acetate Injection, an injectable antagonist; and Jada, for abnormal postpartum uterine bleeding or hemorrhage. The company's biosimilars portfolio consists of immunology products, such as Brenzys, Renflexis, and Hadlima; and two oncology products, including Ontruzant and Aybintio. It offers cholesterol-modifying medicines under the Zetia, Ezetrol, Vytorin, Inegy, Rosuzet, and Zocor brands; Cozaar and Hyzaar for the treatment of hypertension; respiratory products for treatments of control and prevent symptoms caused by asthma under the Singulair, Dulera, Zenhale, and Asmanex brand names; and Singulair, Nasonex, Clarinex, and Aerius for treating seasonal allergic rhinitis. The company provides dermatology products under the Diprosone and Elocon brand; bone health portfolio, including Fosamax brand name; non-opioid pain management products under the Arcoxia, Diprospan, and Celestone brand names; Proscar for the treatment of symptomatic benign prostatic hyperplasia; and Propecia for the treatment of male pattern hair loss. The company sells its products to drug wholesalers and retailers, hospitals, pharmacies, clinics, government agencies, health maintenance organizations, pharmacy benefit managers, and other institutions. The company was incorporated in 2020 and is headquartered in Jersey City, New Jersey.
User Content from Tickernomics. Created by Luminus.
DISCLAIMER

This web site and its creators are not certified financial advisors. All opinions/suggestions expressed on this website should not be treated as specific inducement to make a particular investment or follow a particular strategy, but only as an expression of an opinion.The Company doesn't warrant the information provided on the website for its completeness or accuracy, and it should not be relied upon as such. The Company is not under any obligation to update or correct any information provided on this website.The content of this website is published in the United States of America and persons who access it agree to do so in accordance with applicable U.S. law.Past performance is not indicative of future results. The Company doesn't guarantee any specific outcome or profit. You should be aware of the real risk of loss in following any strategy or investment discussed on this website.Strategies or investments discussed may fluctuate in price or value. Investors may get back less than invested. Investments or strategies mentioned on this website may not be suitable for you. This material does not take into account your particular investment objectives,financial situation or needs and is not intended as recommendations appropriate for you. You must make an independent decision regarding investments or strategies mentioned on this website. Before acting on information on this website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser.